Oppenheimer analyst Matthew Biegler downgraded Cartesian Therapeutics (NASDAQ: RNAC) from Outperform to Perform.The analyst comments "We’ve been bullish on this ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE